International Trade Commission
- [Investigation Nos. 701-TA-808 and 731-TA-1809 (Preliminary)]
On the basis of the record [1] developed in the subject investigations, the United States International Trade Commission (“Commission”) determines, pursuant to the Tariff Act of 1930 (“the Act”), that there is a reasonable indication that an industry in the United States is materially injured by reason of imports of amine compounds from China, provided for in subheadings 2921.29.00, 2922.19.96, and 2934.99.90 of the Harmonized Tariff Schedule of the United States, that are alleged to be sold in the United States at less than fair value (“LTFV”) and imports of the subject merchandise from China that are ( printed page 74194) alleged to be subsidized by the government of China.[2]
Commencement of Final Phase Investigations
Pursuant to section 207.18 of the Commission's rules, the Commission also gives notice of the commencement of the final phase of its investigations. The Commission will issue a final phase notice of scheduling, which will be published in the Federal Register as provided in § 207.21 of the Commission's rules, upon notice from the U.S. Department of Commerce (“Commerce”) of affirmative preliminary determinations in the investigations under §§ 703(b) or 733(b) of the Act, or, if the preliminary determinations are negative, upon notice of affirmative final determinations in those investigations under §§ 705(a) or 735(a) of the Act. Parties that filed entries of appearance in the preliminary phase of the investigations need not enter a separate appearance for the final phase of the investigations. Industrial users, and, if the merchandise under investigation is sold at the retail level, representative consumer organizations have the right to appear as parties in Commission antidumping and countervailing duty investigations. The Secretary will prepare a public service list containing the names and addresses of all persons, or their representatives, who are parties to the investigations. As provided in section 207.20 of the Commission's rules, the Director of the Office of Investigations will circulate draft questionnaires for the final phase of the investigations to parties to the investigations, placing copies on the Commission's Electronic Document Information System (EDIS, edis.usitc.gov), for comment.
Background
On September 29, 2026, Evonik Corporation, Piscataway, New Jersey, and Huntsman International LLC, The Woodlands, Texas, filed petitions with the Commission and Commerce, alleging that an industry in the United States is materially injured or threatened with material injury by reason of subsidized imports of amine compounds from China and LTFV imports of amine compounds from China. Accordingly, effective September 29, 2026, the Commission instituted countervailing duty investigation No. 701-TA-808 and antidumping duty investigation No. 731-TA-1809 (Preliminary).
Notice of the institution of the Commission's investigations and of a public conference to be held in connection therewith was given by posting copies of the notice in the Office of the Secretary, U.S. International Trade Commission, Washington, DC, and by publishing the notice in the Federal Register of October 5, 2026 (91 FR 63307). The Commission conducted its conference on October 20, 2026. All persons who requested the opportunity were permitted to participate.
The Commission made these determinations pursuant to §§ 703(a) and 733(a) of the Act (19 U.S.C. 1671b(a) and 1673b(a)). It completed and filed its determinations in these investigations on November 13, 2026. The views of the Commission are contained in USITC Publication 5817 (November 2026), entitled Amine Compounds from China: Investigation Nos. 701-TA-808 and 731-TA-1809 (Preliminary).
By order of the Commission.
Issued: November 13, 2026.
Sharon Bellamy,
Supervisory Hearings and Information Officer.
Footnotes
1. The record is defined in § 207.2(f) of the Commission's Rules of Practice and Procedure (19 CFR 207.2(f)).
Back to Citation2. 91 FR 67290 and 91 FR 67294 (October 26, 2026).
Back to Citation[FR Doc. 2026-23420 Filed 11-17-26; 8:45 am]
BILLING CODE 7020-02-P